DelveInsight’s, “Osteosarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 30+ Osteosarcoma companies and 30+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including Osteosarcoma clinical trials and nonclinical stage products. Osteosarcoma pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Osteosarcoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Osteosarcoma clinical trials studies, Osteosarcoma NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Osteosarcoma Pipeline Insight Report
- Over 30+ Osteosarcoma companies are evaluating 30+ Osteosarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Osteosarcoma market would significantly increase market revenue.
- The leading Osteosarcoma Companies includes AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd, George Clinical Pty Ltd, Y-mAbs Therapeutics, Jiangsu Hengrui Medicine, AstraZeneca, Advenchen Laboratories LLC, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., Merck & Co, Hutchison Medipharma Limited, MacroGenics, Gradalis, Inc., Shanghai Pharmaceuticals Holding, Celgene, Oncternal Therapeutics, Valent Technologies, and others.
- Promising Osteosarcoma Companies includes Lenvatinib, Ifosfamide, Etoposide, Methotrexate, Calcium Folinate, Pemetrexed, Mifamurtide (L-MTP-PE), Cisplatin liposomal, Inhaled Lipid Cisplatin (ILC), Interferon Alpha, and others.
- The Osteosarcoma companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The Osteosarcoma pipeline therapies under development are focused on novel approaches to treat/improve Osteosarcoma.
To explore more information on the latest breakthroughs in the Osteosarcoma Pipeline treatment landscape of the report, click here @ Osteosarcoma Pipeline Outlook
Osteosarcoma Overview
A “Sarcoma” is a type of cancer that that develops in connective tissue such as bone, cartilage, or muscle and “Osteo” refers to bones. Osteosarcoma or osteogenic sarcoma is a type of cancer that starts in the bones. Osteosarcoma is a rare type of bone cancer in which malignant (cancerous) cells produce irregular bone. Although osteosarcoma can affect people of all ages, it most often occurs in children and teens who are still growing. The tumor usually develops at the ends of the long bones, specifically around the knee and in the shoulder, but can occur anywhere in the body. The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. Pain is the most common symptom of osteosarcoma. This pain may come and go at first but, gradually, it becomes constant. Some patients may have swelling or a mass in the area of the tumor. If the tumors are in the bones of your legs, it may cause limping. However, osteosarcomas can also be painless. Treatment usually involves chemotherapy, surgery and, sometimes, radiation therapy. Diagnosis is based upon medical history and physical examination; imaging tests like X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy.
Emerging Osteosarcoma Drugs Profile
ZKAB-001: Lee’s Pharmaceutical
ZKAB001 is a fully human anti-PD-L1 monoclonal antibody targeting tumor PD-L1 protein. It can release the “brake” causing by the tumor cell to the immune system. A phase I clinical trial in osteosarcoma patients who underwent upfront therapy to evaluate whether ZKAB001 can prevent tumor recurrence was completed early this year and the encouraging results therefrom has led to the initiation of this phase III clinical trial titled “Study of ZKAB001 for Maintenance Therapy in Patients with High-grade Osteosarcoma after Adjuvant Chemotherapy”.
Lenvatinib: Eisai Co Ltd/Merck & Co
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. Currently it is being investigated in Phase II stage of development to provide the potential treatment for the patients with osteosarcoma.
ZN c3: Zentalis Pharmaceuticals
ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.
For further information, refer to the detailed Osteosarcoma Unmet Needs, Osteosarcoma Market Drivers, and Osteosarcoma Market Barriers, click here for Osteosarcoma Ongoing Clinical Trial Analysis
Osteosarcoma Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Osteosarcoma Pipeline Therapeutics Assessment
There are approx. 30+ key Osteosarcoma companies which are developing the therapies for Osteosarcoma. The companies which have their Osteosarcoma drug candidates in the most advanced stage, i.e. phase III include, Lee’s Pharmaceutical.
Request a sample and discover the recent advances in Osteosarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Osteosarcoma Treatment Landscape
Scope of the Osteosarcoma Pipeline Report
- Coverage- Global
- OsteosarcomaCompanies- AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd, George Clinical Pty Ltd, Y-mAbs Therapeutics, Jiangsu Hengrui Medicine, AstraZeneca, Advenchen Laboratories LLC, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., Merck & Co, Hutchison Medipharma Limited, MacroGenics, Gradalis, Inc., Shanghai Pharmaceuticals Holding, Celgene, Oncternal Therapeutics, Valent Technologies, and others.
- Osteosarcoma Pipeline Therapies- Lenvatinib, Ifosfamide, Etoposide, Methotrexate, Calcium Folinate, Pemetrexed, Mifamurtide (L-MTP-PE), Cisplatin liposomal, Inhaled Lipid Cisplatin (ILC), Interferon Alpha, and others.
- Osteosarcoma Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for drugs for Osteosarcoma Market Drivers and Osteosarcoma Market Barriers, click here @ Osteosarcoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Osteosarcoma: Overview
- Osteosarcoma Pipeline Therapeutics
- Osteosarcoma Therapeutic Assessment
- Osteosarcoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ZKAB-001: Lee’s Pharmaceutical
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Lenvatinib: Eisai Co Ltd/Merck & Co
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- ZN c3: Zentalis Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Osteosarcoma Key Companies
- Osteosarcoma Key Products
- Osteosarcoma- Unmet Needs
- Osteosarcoma- Market Drivers and Barriers
- Osteosarcoma- Future Perspectives and Conclusion
- Osteosarcoma Analyst Views
- Osteosarcoma Key Companies
- Appendix
Got Queries? Find out the related information on Osteosarcoma Mergers and acquisitions, Osteosarcoma Licensing Activities @ Osteosarcoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services